Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by BTIG Research in a report released on Monday, Benzinga reports. They presently have a $151.00 target price on the stock. BTIG Research‘s price objective would suggest a potential upside of 85.57% from the company’s current price.

Several other equities research analysts have also recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Wedbush set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 24th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded up $2.28 during midday trading on Monday, hitting $81.37. The company had a trading volume of 146,319 shares, compared to its average volume of 1,083,880. Oruka Therapeutics has a twelve month low of $25.11 and a twelve month high of $115.51. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of -40.20 and a beta of -0.37. The business’s 50-day simple moving average is $91.32 and its 200-day simple moving average is $80.65.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts forecast that Oruka Therapeutics will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Oruka Therapeutics news, CEO Lawrence Klein sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total transaction of $2,090,500.00. Following the completion of the sale, the chief executive officer owned 923,128 shares of the company’s stock, valued at $77,191,963.36. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares of the company’s stock, valued at approximately $1,146,051.40. This trade represents a 41.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 154,950 shares of company stock valued at $14,102,680 over the last quarter. 23.49% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. Nykredit A S acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at $29,000. GAMMA Investing LLC grew its stake in shares of Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares in the last quarter. Orion Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at $91,000. Natural Investments LLC acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at $202,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $67,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.